MedTrace Logo

Angio-seal VIP Versus Perclose ProGlide for Closure of the Femoral Artery in Peripheral Vascular Disease

NCT05334095 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1062

Last updated 2022-04-19

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy (device deployment characteristics and performance) and safety (adverse access site related events) of Perclose ProGlide (Abbott Vascular Devices) for femoral access site closure in patients undergoing peripheral vascular diagnostic and interventional procedures in comparison with Angio-seal VIP (St. Jude Medical).

Conditions

  • Peripheral Vascular Diseases
  • Percutaneous Intervention Via Femoral Artery

Interventions

DEVICE

Perclose ProGlide

After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.

DEVICE

Angio-seal VIP

After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP

Sponsors & Collaborators

  • Xiongjing Jiang

    lead OTHER

Principal Investigators

  • Xiongjing Jiang, MD · Fuwai Hospital, National Center for Cardiovascular Disease

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-20
Primary Completion
2022-06-01
Completion
2022-09-01
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05334095 on ClinicalTrials.gov